Celsion Corporation (NASDAQ: CLSN) to Ring The NASDAQ Stock Market Closing Bell
July 15 2014 - 10:00AM
ADVISORY, July 15, 2014 (GLOBE NEWSWIRE) --
What:
Celsion Corporation (Nasdaq:CLSN), a leading oncology drug
development company, will visit the NASDAQ MarketSite in Times
Square.
In honor of the occasion, Michael Tardugno, Chief
Executive Officer will ring the Closing Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway –
Broadcast Studio
When:
Wednesday, July 16, 2014 – 3:45 p.m. to 4:00 p.m. ET
Celsion Corporation Media Contact: Jeffrey W.
Church Sr. Vice President and CFO 609-482-2455
jchurch@celsion.com
NASDAQ MarketSite: Christine Barna (646)
441-5310 Christine.Barna@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC
3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo
postings, status updates and video of bell ceremonies please visit
our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page:
http://instagram.com/nasdaq.
For news tweets, please visit our Twitter page at:
http://twitter.com/nasdaqomx.
For exciting viral content and ceremony photos visit Tumblr
Page: http://nasdaq.tumblr.com/.
Webcast:
A webcast of the NASDAQ Closing Bell will be available at:
https://new.livestream.com/nasdaq/live or
http://www.nasdaq.com/about/marketsitetowervideo.asx.
Photos:
To obtain a hi-resolution photograph of the Market Close, please
go to http://www.nasdaq.com/reference/marketsite_events.stm and
click on the market close of your choice.
About Celsion Corporation (Nasdaq:CLSN):
Celsion is fully-integrated oncology company focused on
developing a portfolio of innovative cancer treatments, including
directed chemotherapies, immunotherapies and RNA- or DNA-based
therapies. The Company's lead program is ThermoDox®, a proprietary
heat-activated liposomal encapsulation of doxorubicin, currently in
Phase III development for the treatment of primary liver cancer.
The pipeline also includes EGEN-001, a DNA-based immunotherapy for
the localized treatment of ovarian and brain cancers. Celsion has
three platform technologies for the development of novel nucleic
acid-based immunotherapies and other anti-cancer DNA or RNA
therapies, including TheraPlasTM, TheraSilenceTM and RASTTM. For
more information on Celsion, visit our website:
http://www.celsion.com.
About NASDAQ OMX Group
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading,
exchange technology, information and public company services across
six continents. Through its diverse portfolio of solutions, NASDAQ
OMX enables customers to plan, optimize and execute their business
vision with confidence, using proven technologies that provide
transparency and insight for navigating today's global capital
markets. As the creator of the world's first electronic stock
market, its technology powers more than 70 marketplaces in 50
countries, and 1 in 10 of the world's securities transactions.
NASDAQ OMX is home to more than 3,400 listed companies with a
market value of over $8.5 trillion and more than 10,000 corporate
clients. To learn more, visit www.nasdaqomx.com.
-NDAQA-
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Oct 2023 to Oct 2024